Emerging Competition Issues Involving Follow-On Biologics

7 Pages Posted: 12 Dec 2014

Date Written: 2014


In 2010, President Obama signed into law the Biologics Price Competition and Innovation Act, which created an abbreviated approval pathway for competing versions of previously-approved biologics. Passage of this legislation and the impending introduction of follow-on biologics, or biosimilars, into the marketplace raise the question of whether biologic product manufacturers will have to contend with the same antitrust scrutiny of their intellectual property litigation settlement agreements, life cycle management, and marketing practices that pharmaceutical drug firms have faced. In this article, we examine four ways in which pharmaceutical firms have allegedly delayed product entry in violation of the antitrust laws — reverse-payment settlements, REMS-based distribution restrictions, false Orange Book listings, and product hopping — and examine whether this conduct is likely to occur in the context of biologics and how the antitrust analysis of this conduct may differ for biologics.

Keywords: biologic, biosimilar, follow-on biologic, FOB, BPCIA, antitrust, competition, FTC, FDA

JEL Classification: I18, K21, K23, L40, L41, L42, L43, L44, L49

Suggested Citation

Tucker, Darren S. and Wells, Gregory, Emerging Competition Issues Involving Follow-On Biologics (2014). Antitrust Magazine, Vol. 29, No. 1, 2014. Available at SSRN: https://ssrn.com/abstract=2536969

Darren S. Tucker (Contact Author)

Vinson & Elkins LLP ( email )

2200 Pennsylvania Ave NW
Washington, DC 20037
United States

Gregory Wells

Vinson & Elkins LLP ( email )

2200 Pennsylvania Ave., NW
Washington, DC 20037
United States

Register to save articles to
your library


Paper statistics

Abstract Views
PlumX Metrics

Under construction: SSRN citations while be offline until July when we will launch a brand new and improved citations service, check here for more details.

For more information